European Trial Begins Subcutaneous EEG Study in Epilepsy

A new European clinical trial has begun testing subcutaneous EEG technology in people with epilepsy. The multicenter evaluation represents one of the first systematic European assessments of an under-the-skin electrode approach positioned between standard scalp recordings and intracranial monitoring.

What is subcutaneous EEG?

Subcutaneous EEG refers to brain electrical activity recorded from electrodes placed beneath the skin of the scalp but above the skull, rather than on the skin surface or within the cranial vault. The configuration aims to capture the chronic stability of implanted devices while avoiding the surgical morbidity of intracranial depth or strip electrodes. It also seeks to reduce the signal attenuation that limits scalp recordings during ambulatory use.

Investigators have explored the technique for more than a decade as a means of obtaining weeks-to-months of continuous electrophysiological data in patients' normal environments, a window inaccessible to routine scalp EEG and impractical for intracranial monitoring outside the presurgical workup.

What endpoints will the trial assess?

The European study will evaluate subcutaneous EEG in epilepsy patients. Such trials typically follow a standard pathway for novel neurophysiology devices: first-in-human safety and feasibility, then multicenter concordance studies against the video-EEG gold standard, and finally pivotal trials sized to support regulatory clearance.

Primary endpoints in this class of study generally include:

• Recording durability across the implantation period
• Signal quality sufficient for clinical interpretation
• Sensitivity and specificity of seizure detection versus scalp video-EEG
• Adverse event rates compared with established long-term monitoring
• Patient comfort and cosmetic outcomes

Why does the technology matter now?

Epilepsy monitoring confronts a fundamental coverage gap. Standard scalp EEG captures hours to a few days, and patients with infrequent seizures frequently leave the epilepsy monitoring unit without diagnostic events. Ambulatory scalp EEG extends the window to days, but motion artifact, electrode detachment, and limited spatial sampling constrain interpretation. Intracranial EEG delivers high-fidelity data but carries surgical risks reserved for drug-resistant presurgical candidates.

Subcutaneous systems target the middle ground: continuous outpatient recording over weeks or months, with data stored on an implanted or body-worn recorder and reviewed asynchronously by clinical neurophysiologists. The trade-off — signal-to-noise ratio and spatial resolution lower than intracranial leads but higher than scalp surface recordings — defines both the technology's promise and its clinical limits.

How will it change reading-room practice?

A validated subcutaneous platform would shift portions of long-term epilepsy monitoring out of dedicated epilepsy monitoring units and into outpatient practice. Clinical neurophysiology services would need to adjust reading workflows, data storage, and reimbursement pathways to accommodate continuous recordings spanning months rather than days.

Event detection will depend on automated algorithms reviewed by technologists and physicians, raising questions about annotation standards and thresholds for clinical action. Practices will also need to distinguish investigational subcutaneous recordings from FDA-cleared or CE-marked long-term scalp ambulatory devices, which already permit days of outpatient monitoring but with different signal characteristics.

What comes next?

The European trial joins a small but growing portfolio of multicenter evaluations of subcutaneous EEG and similar minimally invasive electrophysiology platforms. Publication of full results — including concordance data against video-EEG, device longevity, and adverse event profiles — will determine whether the modality enters routine clinical neurophysiology or remains confined to research settings.